alendronate / Generic mfg. 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«123456789101112»
  • ||||||||||  alendronate / Generic mfg.
    Journal:  Efficacy and Safety of Generic Alendronate for Osteoporosis Treatment. (Pubmed Central) -  Feb 27, 2024   
    Three patients discontinued the medication due to adverse effects: two had dyspepsia, and one had persistent myalgia. Generic alendronate may be considered an effective antiresorptive agent for osteoporosis treatment with a low incidence of adverse effects.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Retrospective data, Review, Journal:  Anti-osteoporotic drug efficacy for periprosthetic bone loss after total hip arthroplasty: A systematic review and network meta-analysis. (Pubmed Central) -  Feb 12, 2024   
    Apart from further enriching the genera Amazonocrinis and Dendronalium, the current study helps to resolve the taxonomic complexities revolving around the genus Amazonocrinis and aims to attract researchers to the continued exploration of the tropical and subtropical cyanobacteria for interesting taxa and lineages. Bisphosphonate and denosumab may be effective anti-osteoporotic drugs for preventing periprosthetic proximal femoral bone loss due to stress shielding after THA, particularly in cementless proximal fixation stems, which are the most commonly used prostheses worldwide.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Journal:  Clinical application of bone turnover markers in osteoporosis. (Pubmed Central) -  Feb 8, 2024   
    This review describes how BTM can be used for treatment monitoring, including monitoring during discontinuation of alendronate and denosumab therapy. In addition, sources of errors and pitfalls when using BTM monitoring will be described.
  • ||||||||||  Prolia (denosumab) / Amgen
    Trial completion, Trial completion date, Trial primary completion date:  Bisphosphonates for Prevention of Post-Denosumab Bone Loss (clinicaltrials.gov) -  Feb 5, 2024   
    P2,  N=27, Completed, 
    The double-layer soft tissue suture closure technique can achieve good clinical results in patients with MRONJ of the mandible using anti-bone-resorptive drugs alone, and can provide clinical treatment ideas for MRONJ patients with more complicated drug use. Active, not recruiting --> Completed | Trial completion date: Jan 2025 --> Jun 2023 | Trial primary completion date: Jan 2024 --> Jun 2023
  • ||||||||||  alendronate / Generic mfg.
    Journal:  Polydopamine-Modified Titanium Dioxide Nanotube Arrays Doped with Calcium as a Sustained Drug Delivery System. (Pubmed Central) -  Feb 5, 2024   
    Sodium alendronate (NaAL) was used as a model drug and loaded onto TNTs-PDA-Ca2+ by immersing them in an NaAL solution...Furthermore, acidic conditions can cause significant drug release due to the cleavage of coordination bonds between the drug and Ca2+ ions. Thus, the aforementioned drug delivery system represents a potentially promising approach for achieving sustained and controllable drug release.
  • ||||||||||  alendronate / Generic mfg.
    Preclinical, Journal:  Bisphosphonates do not affect healing of a critical-size defect in estrogen-deficient mice. (Pubmed Central) -  Feb 2, 2024   
    Eight weeks later, after the manifestation of ovariectomy-induced osteoporotic bone changes, BP therapy with Alendronate (ALN) was commenced...The present study provides evidence that continuous administration of BP does not inhibit implant resorption and does not alter the kinetics of the healing process of critical-size long bone defects. Furthermore, the BMP2 variant L51P did not enhance the bioefficacy of BMP2 when applied simultaneously to the femoral critical-size defect in sham and OVX mice.
  • ||||||||||  alendronate / Generic mfg.
    Preclinical, Journal:  Lactobacillus plantarum attenuates glucocorticoid-induced osteoporosis by altering the composition of rat gut microbiota and serum metabolic profile. (Pubmed Central) -  Jan 28, 2024   
    This study aimed to evaluate the beneficial effects of the probiotic Lactobacillus plantarum on bone health and its underlying mechanisms in a rat model of glucocorticoid dexamethasone-induced osteoporosis, using the osteoporosis treatment drug alendronate as a reference...Lactobacillus plantarum can protect rats from DEX-induced GIOP by mediating the "gut microbial-bone axis" promoting the production of beneficial bacteria and metabolites. Therefore L. plantarum is a potential candidate for the treatment of GIOP.
  • ||||||||||  chloroquine phosphate / Generic mfg., alendronate / Generic mfg.
    Preclinical, Journal:  Quercetin suppresses ovariectomy-induced osteoporosis in rat mandibles by regulating autophagy and the NLRP3 pathway. (Pubmed Central) -  Jan 23, 2024   
    (IL-1?) and interleukin-18 (IL-18) on the nucleotide-binding oligomerization domain (NOD)-like receptor (NLR) protein 3 (NLRP3) pathway thereby inhibiting osteoclast differentiation, immunofluorescence and western blotting also confirmed that QR inhibited autophagy in OVX rats and suppressed the number of tartrate-resistant acid phosphatase (TRAP)-stained positive osteoclasts. The findings suggest that QR may protect the bone structure and prevent bone loss in osteoporotic rats by inhibiting the NLRP3 pathway and autophagy in osteoclasts with comparable effects to ALN, thus QR may have the potential to be a promising alternative supplement for the preventive and therapeutic treatment of PMOP.
  • ||||||||||  alendronate / Generic mfg.
    Journal:  Study of Injectable Hydrogel Based on ALN/Nha Promoting Osteogenesis And Inhibiting Osteoclasts in Osteoporotic Bone Defects Repair. (Pubmed Central) -  Jan 12, 2024   
    Additionally, alendronate sodium (ALN) was loaded into the hydrogel through Schiff base formation with OSA, and nanohydroxyapatite (nHA) was incorporated into the hydrogel via blending...Cell studies indicated that the hydrogel can promote the differentiation of osteoblasts and inhibit the activity osteoclast, so as to obtain better osteogenic effect. Therefore, the injectable hydrogel can be used to repair osteoporotic bone defects through a minimally invasive, simple treatment modality.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Enrollment closed, Trial completion date, Trial primary completion date:  Denosumab (DMAB) Discontinuation And Switching In Glucocorticoid-Induced Osteoporosis (GIOP): A Pilot Study (clinicaltrials.gov) -  Jan 9, 2024   
    P4,  N=45, Active, not recruiting, 
    Therefore, the injectable hydrogel can be used to repair osteoporotic bone defects through a minimally invasive, simple treatment modality. Recruiting --> Active, not recruiting | Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Jan 2024 --> Dec 2024
  • ||||||||||  alendronate / Generic mfg.
    Review, Journal:  Chemical and Structural Engineering of Gelatin-Based Delivery Systems for Therapeutic Applications: A Review. (Pubmed Central) -  Jan 4, 2024   
    We emphasized the advantages of various gelatin derivatives, including methacryloyl gelatin, polyethylene glycol-modified gelatin, thiolated gelatin, and alendronate-modified gelatin...While discussing the current limitations, we also addressed the challenges that need to be overcome for clinical translation, including high manufacturing costs, limited application scenarios, and potential immunogenicity. This Review provides insight into how the structural and chemical engineering of gelatin can be leveraged to pave the way for significant advancements in biomedical applications and the improvement of patient outcomes.
  • ||||||||||  Jakafi (ruxolitinib) / Novartis, Incyte
    Journal:  CD45 inhibition in myeloid leukaemia cells sensitizes cellular responsiveness to chemotherapy. (Pubmed Central) -  Jan 3, 2024   
    Bioinformatics analysis identified genes whose expression was correlated with CD45 expression such as JAK2, ACTR2, THAP3 Serglycin, and PBX-1 genes, as well as licensed drugs (alendronate, allopurinol, and balsalazide), which could be repurposed as CD45 inhibitors which effectively increases sensitivity to cytarabine and ruxolitinib at low doses. Therefore, CD45 inhibition could be explored as a potential therapeutic partner for treatment of myeloid malignancies in combination with chemotherapy such as cytarabine especially for elderly patients and those showing chemotherapy resistance.
  • ||||||||||  5-fluorouracil / Generic mfg., temozolomide / Generic mfg., alendronate / Generic mfg.
    Journal:  Interactions between ?-cyclodextrin as a carrier for anti-cancer drug delivery: a molecular dynamics simulation study. (Pubmed Central) -  Dec 5, 2023   
    Especially for those drugs that were able to penetrate to the end of the primary hydroxyl rim of the ?CD, that means TMZ and 5-Fu. Meanwhile, due to the lack of Ald penetration to the end of the primary hydroxyl rim, the area change in the Ald-containing system was less than in the two others.Communicated by Ramaswamy H. Sarma.
  • ||||||||||  alendronate / Generic mfg.
    Trial initiation date:  Alendronate for Hip Osteonecrosis in Adults With Sickle Cell Disease (clinicaltrials.gov) -  Dec 5, 2023   
    P2,  N=24, Not yet recruiting, 
    Meanwhile, due to the lack of Ald penetration to the end of the primary hydroxyl rim, the area change in the Ald-containing system was less than in the two others.Communicated by Ramaswamy H. Sarma. Initiation date: Oct 2023 --> Jan 2024
  • ||||||||||  alendronate / Generic mfg.
    Trial completion:  ALOSTRA: Alendronate Treatment of Osteoporosis in Rheumatoid Arthritis (clinicaltrials.gov) -  Nov 27, 2023   
    P2,  N=69, Completed, 
    Our findings indicated that the effects of ALN on hPDLSCs behavior are dose-dependent and suggest a role for oxidative stress in ALN-induced cell death that may lead to novel therapeutic approaches for ONJ. Active, not recruiting --> Completed
  • ||||||||||  alendronate / Generic mfg., doxorubicin hydrochloride / Generic mfg.
    Journal:  Harnessing Nanomedicine to Potentiate the Chemo-Immunotherapeutic Effects of Doxorubicin and Alendronate Co-Encapsulated in Pegylated Liposomes. (Pubmed Central) -  Nov 25, 2023   
    Results of biodistribution studies, imaging with radionuclide-labeled liposomes, and therapeutic studies as a single agent and in combination with immune checkpoint inhibitors or gamma-delta T lymphocytes suggest that PLAD is a unique product with distinct tumor microenvironmental interactions and distinct pharmacologic properties when compared with free Dox and the clinical formulation of pegylated liposomal Dox. These results underscore the potential added value of PLAD for chemo-immunotherapy of cancer and the relevance of the co-encapsulation approach in nanomedicine.
  • ||||||||||  alendronate / Generic mfg.
    Journal:  Ca-AlN MOFs-loaded Chitosan/gelatin scaffolds; a dual-delivery system for bone tissue engineering applications. (Pubmed Central) -  Nov 22, 2023   
    The objective of this research is to create a composite scaffold using chitosan/gelatin (CHS/Gel) and the calcium (Ca)-alendronate (ALN) metal-organic frameworks (MOFs)...The release profile results showed that the NPs-loaded CHS/Gel scaffolds were able to simultaneously release ALN and Ca ions due to the decomposition of NPs. Additionally, the loading of NPs in the CHS/Gel scaffold led to an increment in alkaline phosphatase (ALP) activity and the quantity of deposited Ca along with osteogenesis gene markers.These findings suggest that the NPs-loaded CHS/Gel scaffold has the potential to enhance the differentiation of human adipose tissue-derived mesenchymal stem cells, making it a promising approach for bone repair. .
  • ||||||||||  alendronate / Generic mfg.
    Journal:  Zuogui Wan alleviates ovariectomy-induced osteoporosis by maintaining FoxO3 and increasing NK1R. (Pubmed Central) -  Nov 17, 2023   
    Rats subjected to sham and OVX were treated with the vehicle, alendronate, and Zuogui Wan (ZGW) at the doses of low, medium and high lyophilized powder daily for 3 months, respectively...In addition, we found ZGW upregulated for the NK1R mRNA or protein expression by promoting the expression level of transcription factor FoxO3 and increasing its binding to the NK1R promoter region -700/-200 sequence. These results suggest that the regulation of FoxO3 and NK1R played a role and contributed to the mechanism of ZGW underlying the increase in bone mass in the OVX rat model.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Retrospective data, Journal, Surgery:  Efficacy and safety of different anti-osteoporotic drugs for the spinal fusion surgery: A network meta-analysis. (Pubmed Central) -  Nov 16, 2023   
    This network meta-analysis suggests that teriparatide combined with denosumab and teriparatide alone significantly increase the fusion rate and decrease the ODI without increasing adverse events. Based on current evidence, teriparatide combined with denosumab or teriparatide alone is recommended to increase the fusion rate and to reduce ODI in spinal fusion patients.
  • ||||||||||  zoledronic acid / Generic mfg., alendronate / Generic mfg.
    Review, Journal:  Long-term consequences of osteoporosis therapy with bisphosphonates. (Pubmed Central) -  Nov 14, 2023   
    BPs have demonstrated safety and effectiveness throughout the years and evidenced increased BMD and reduced fracture risks, resulting in reduced morbimortality, and improved quality of life. These benefits overweight the risks of rare adverse events.